BRPI0517341A - shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound - Google Patents

shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound

Info

Publication number
BRPI0517341A
BRPI0517341A BRPI0517341-8A BRPI0517341A BRPI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A BR PI0517341 A BRPI0517341 A BR PI0517341A
Authority
BR
Brazil
Prior art keywords
glp
compound
stable
preparation
pharmaceutical composition
Prior art date
Application number
BRPI0517341-8A
Other languages
Portuguese (pt)
Inventor
Svend Ludvigsen
Morten Schlein
Boving Tine Elisabeth Gottschalk
Claude Bonde
Anne-Mette Lilleore
Engelund Dorthe Kot
Bjarne Ronfeldt Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39560969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517341(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2005/055916 external-priority patent/WO2006051103A2/en
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0517341A publication Critical patent/BRPI0517341A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPOSIçãO FARMACêUTICA ESTáVEL EM PRATELEIRA, MéTODOS PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA, PARA O TRATAMENTO DE HIPERGLICEMIA, PARA O TRATAMENTO DE OBESIDADE, DEFICIêNCIA DE CéLULA BETA, IGT OU DISLIPIDEMIA, PARA A PREPARAçáO DE UMA SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1, PARA A PREPARAçãO DE UM COMPOSTO GLP-1 ESTAVEL E PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA ESTáVEL EM PRATELEIRA DE UM COMPOSTO GLP-1, SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1, E, USO DE UMA SOLUçãO ESTáVEL DE UM COMPOSTO GLP-1. Composição farmacêutica estável compreendendo peptídeo insulmotrópico.PHARMACEUTICAL COMPOSITION STABLE IN SHELF, METHODS FOR PREPARING A PHARMACEUTICAL COMPOSITION, FOR THE TREATMENT OF HYPERGLYCEMIA, THE DEFICIENCY OF BETA CELL, A SOLT BEFORE, A PRE-DIAPLE SOLT FOR PREPARATION OF A STABLE GLP-1 COMPOUND AND FOR PREPARATION OF A STABLE PHARMACEUTICAL COMPOSITION OF A GLP-1 COMPOUND, STABLE SOLUTION OF A GLP-1 COMPOUND, AND USE OF A STABLE SOLUTION OF A GLP-1 COMPOUND . Stable pharmaceutical composition comprising insulmotropic peptide.

BRPI0517341-8A 2004-11-12 2005-11-14 shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound BRPI0517341A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA200401753 2004-11-12
DKPA200401906 2004-12-08
EP05104050 2005-05-13
EP05104172 2005-05-18
PCT/EP2005/055916 WO2006051103A2 (en) 2004-11-12 2005-11-11 Stable formulations of peptides
PCT/EP2005/055946 WO2006051110A2 (en) 2004-11-12 2005-11-14 Stable formulations of insulinoptropic peptides

Publications (1)

Publication Number Publication Date
BRPI0517341A true BRPI0517341A (en) 2008-10-07

Family

ID=39560969

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517341-8A BRPI0517341A (en) 2004-11-12 2005-11-14 shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound

Country Status (13)

Country Link
US (1) US8748376B2 (en)
EP (2) EP2494983B1 (en)
JP (1) JP5175103B2 (en)
KR (1) KR101340354B1 (en)
CN (3) CN106137952B (en)
AU (1) AU2005303777B2 (en)
BR (1) BRPI0517341A (en)
CA (1) CA2586771A1 (en)
ES (2) ES2458991T3 (en)
MX (1) MX2007005521A (en)
PL (1) PL1817048T3 (en)
RU (1) RU2413530C9 (en)
WO (1) WO2006051110A2 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
PL1817048T3 (en) 2004-11-12 2014-07-31 Novo Nordisk As Stable formulations of insulinoptropic peptides
WO2006051103A2 (en) * 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7998927B2 (en) * 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
JPWO2009116575A1 (en) 2008-03-19 2011-07-21 アークレイ株式会社 Color former stabilizer and use thereof
DK2271347T3 (en) 2008-03-28 2016-08-15 Hale Biopharma Ventures Llc Administration of benzodiazepine compositions
RS56632B1 (en) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Combination of an insulin and a glp-1 agonist
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
ES2855146T3 (en) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
PT3345593T (en) 2009-11-13 2023-11-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
DE102010011919A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP5759211B2 (en) * 2011-03-11 2015-08-05 三洋化成工業株式会社 Freeze drying method
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN103917241A (en) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
SG11201407137PA (en) 2012-05-03 2014-11-27 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
CA2877056A1 (en) 2012-07-01 2014-01-09 Novo Nordisk A/S Use of long-acting glp-1 peptides
WO2014016300A1 (en) 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
CN104902919B (en) 2012-12-21 2018-11-20 赛诺菲 GLP1/GIP dual agonists or the triple agonists of GLP1/GIP/ glucagon
CN103893744B (en) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 A kind of pharmaceutical preparation for treating diabetes and preparation method thereof
KR20140088837A (en) * 2013-01-03 2014-07-11 한미약품 주식회사 Insulinotropic peptide derivative wherein its N-terminal charge is modified
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN103405753B (en) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 Stable insulin secretion accelerating peptide liquid drugs injection pharmaceutical composition
BR112016008115B1 (en) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh ACYLATED GLUCAGON ANALOGS
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016009995B1 (en) 2013-11-06 2023-04-18 Zealand Pharma A/S TRIPLE AGONIST COMPOUNDS GLUCAGON-GLP-1-GIP
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
TW201609799A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/GIP receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (en) 2013-12-13 2016-03-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3091964A1 (en) 2014-01-09 2016-11-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
BR112016013832A2 (en) 2014-01-09 2017-08-08 Sanofi Sa USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP6898231B6 (en) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ GIP agonist compounds and methods
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
ES2763329T3 (en) 2015-04-16 2020-05-28 Zealand Pharma As Acylated glucagon analog
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
RU2018101070A (en) * 2015-06-16 2019-07-16 Сан Фарма Эдвэнтс Рисёрч Кампани Лимитэд LYRAGLUTIDE-CONTAINING COMPOSITION OF LONG-TERM ACTION FOR THE TREATMENT OF DISEASES OF SUBSTANCES EXCHANGE
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
TW201832783A (en) 2016-12-02 2018-09-16 法商賽諾菲公司 Conjugates comprising an glp-1/glucagon dual agonist, a linker and hyaluronic acid
WO2019120480A1 (en) 2017-12-19 2019-06-27 Novo Nordisk A/S Solubility of glp-1 peptide
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
EP3897570A1 (en) * 2018-12-19 2021-10-27 KRKA, d.d., Novo mesto Pharmaceutical composition comprising glp-1 analogue
EA202192094A1 (en) * 2019-02-06 2021-11-29 Энзин Биосайенсиз Лимитед ANALOGUE OF AGONIST GLUCAGON-LIKE PEPTIDE-1 (GLP-1), METHOD OF ITS PREPARATION AND APPLICATION
WO2020208541A1 (en) * 2019-04-08 2020-10-15 Enzene Biosciences Limited Composition comprising glp-1 analogue
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN116829172A (en) * 2021-02-25 2023-09-29 杭州九源基因工程有限公司 Treatment method of stable liraglutide pharmaceutical preparation
CN116832147B (en) * 2023-08-28 2023-11-07 谛邈生物科技(北京)有限公司 GLP1 polypeptide drug freeze-dried flash release tablet and preparation method thereof

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3641115A1 (en) * 1986-12-02 1988-06-16 Lentia Gmbh METHOD FOR PRODUCING AN INTRAVENOUS APPLICABLE AND STABLE IN LIQUID FORM IMMUNOGLOBULINS
AU616411B2 (en) 1987-05-14 1991-10-31 Commonwealth Scientific And Industrial Research Organisation Whey protein fractions
CA1337024C (en) 1988-06-21 1995-09-19 Yoshie Kurihara Method for stabilizing taste-modifier
EP0422124A4 (en) 1988-06-27 1991-10-16 Genex Corporation Thermal release of recombinant protein into culture media
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE4002066A1 (en) 1990-01-25 1991-08-01 Basf Ag METHOD FOR SEPARATING RIBOFLAVIN FROM FERMENTATION SUSPENSIONS
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (en) 1991-05-07 1991-05-07 Tomas Moks PEPTIDE HORMONE SOLUTION
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DK36492D0 (en) 1992-03-19 1992-03-19 Novo Nordisk As PREPARATION
DE69307505T2 (en) 1992-05-13 1997-07-24 Sandoz Ag OPTHALMIC COMPOSITIONS CONTAINING A CYCLOSPORIN
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
PT729362E (en) 1993-11-19 2000-06-30 Searle & Co TRANSDERMAL COMPOSITION OF N-PHENYL-ALPHA-L-FENILLALANIN OR ESTERS AND ITS PHARMACEUTICALLY ACCEPTED SALTS
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995022560A1 (en) 1994-02-22 1995-08-24 The Syntex-Synergen Neuroscience Joint Venture Pharmaceutical formulations of cntf
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
ES2211889T3 (en) 1994-08-31 2004-07-16 Mitsubishi Pharma Corporation PROCEDURE FOR PURIFICATION OF RECOMBINANT SERUM ALBUMIN.
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
JPH10511365A (en) 1994-12-23 1998-11-04 ノボ ノルディスク アクティーゼルスカブ Delayed GLP-1 composition
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DK0828753T3 (en) 1995-06-02 2003-06-30 Novozymes As A1 / Fe treatment of a protein solution followed by membrane concentration
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
DE19530865A1 (en) * 1995-08-22 1997-02-27 Michael Dr Med Nauck Active ingredient and agent for parenteral nutrition
JPH10101696A (en) 1996-08-08 1998-04-21 Shinotesuto:Kk Removal of contaminants included in protein expressed in transformant and purified protein therefrom
US6384016B1 (en) 1998-03-13 2002-05-07 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
HU227021B1 (en) 1996-08-30 2010-05-28 Novo Nordisk As Glp-1 derivatives
CA2278199A1 (en) 1997-01-20 1998-07-23 Japan Energy Corporation Method for stabilizing peptides and freeze-dried medicinal compositions containing peptides obtained by using the method
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
DE69738333T2 (en) 1997-10-01 2008-11-27 Novadel Pharma Inc. Non-polar spray for buccal administration
RU2218344C2 (en) 1997-10-10 2003-12-10 Родиа Лимитед Rubber adhesion intensifiers
EP1025126B1 (en) 1997-10-24 2003-04-16 Genentech, Inc. Purification of molecules
CA2312190A1 (en) * 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
JP2002504518A (en) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivatives with helix-content of more than 25% forming partially structured micellar-like aggregates
ATE466028T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As N-TERMINALLY MODIFIED GLP-1 DERIVATIVES
ATE466027T1 (en) 1998-02-27 2010-05-15 Novo Nordisk As DERIVATIVES OF GLP-1 ANALOGUE
US6245572B1 (en) 1998-05-01 2001-06-12 University Of Tennessee Research Corporation Flow cytometric characterization of amyloid fibrils
ES2216447T3 (en) * 1998-08-17 2004-10-16 Pfizer Products Inc. STABILIZED PROTEIN COMPOSITIONS.
US6440930B1 (en) 1998-09-17 2002-08-27 Eli Lilly And Company Protein formulations
ES2249933T3 (en) * 1998-12-22 2006-04-01 Eli Lilly And Company SELF-STABLE FORMULATION OF PEPTIDE 1 GLUCAGON TYPE.
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6444788B1 (en) 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
WO2000055119A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
CA2369839A1 (en) * 1999-06-25 2001-01-04 Minimed, Inc. Compositions of insulin and insulin-related peptide for treating diabetes
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
EP1242121B1 (en) 1999-12-16 2005-02-09 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2001051071A2 (en) 2000-01-11 2001-07-19 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
EP1257577B1 (en) 2000-01-27 2004-04-21 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (glp-1) compounds
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) * 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
DZ3388A1 (en) 2000-06-16 2001-12-27 Lilly Co Eli Glucagon peptide 1 analogs
JP4798833B2 (en) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 Method for producing human serum albumin including heat treatment step
US7199217B2 (en) * 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
MXPA03005135A (en) 2000-12-13 2003-12-04 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides.
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
JP4280070B2 (en) 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド Long-lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
AU2002235731A1 (en) 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
EP1391209A4 (en) 2001-05-30 2009-12-16 Chugai Pharmaceutical Co Ltd Protein formulations
ES2298378T3 (en) * 2001-06-28 2008-05-16 Novo Nordisk A/S STABLE FORMULATION OF MODIFIED GLP-1.
CN1335182A (en) 2001-08-08 2002-02-13 华中科技大学 Insulin spray for oral cavity and its prepn process
US7238663B2 (en) 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
MXPA04003569A (en) 2001-10-19 2004-07-23 Lilly Co Eli Biphasic mixtures of glp-1 and insulin.
EP1344533B1 (en) 2002-03-15 2006-08-23 Natimmune A/S Pharmaceutical compositions comprising mannose binding lectin
JP2005535569A (en) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス GLP-1 agonists and cardiovascular complications
ES2308029T3 (en) 2002-09-25 2008-12-01 Novo Nordisk A/S PURIFICATION PROCESS THAT INCLUDES A MICROFILTRATION AT HIGH TEMPERATURES.
US7229554B2 (en) * 2002-09-25 2007-06-12 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
GB0229287D0 (en) 2002-12-16 2003-01-22 Dna Res Innovations Ltd Polyfunctional reagents
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
MXPA05013048A (en) 2003-06-03 2006-03-02 Novo Nordisk As Stabilized pharmaceutical peptide compositions.
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1684793B1 (en) * 2003-11-13 2011-09-21 Novo Nordisk A/S Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
WO2006025882A2 (en) * 2004-08-25 2006-03-09 The Uab Research Foundation Absorption enhancers for drug administration
PL1817048T3 (en) 2004-11-12 2014-07-31 Novo Nordisk As Stable formulations of insulinoptropic peptides

Also Published As

Publication number Publication date
EP1817048B1 (en) 2014-02-12
WO2006051110A2 (en) 2006-05-18
AU2005303777A1 (en) 2006-05-18
CN106137952A (en) 2016-11-23
CN102772787A (en) 2012-11-14
RU2413530C9 (en) 2021-05-18
CN106137952B (en) 2020-11-17
MX2007005521A (en) 2007-05-18
US8748376B2 (en) 2014-06-10
EP2494983B1 (en) 2019-04-24
RU2007116157A (en) 2008-12-20
EP2494983A1 (en) 2012-09-05
ES2458991T3 (en) 2014-05-07
EP1817048A2 (en) 2007-08-15
WO2006051110A3 (en) 2006-11-02
CN105832658A (en) 2016-08-10
ES2735533T3 (en) 2019-12-19
RU2413530C2 (en) 2011-03-10
KR101340354B1 (en) 2013-12-11
PL1817048T3 (en) 2014-07-31
US20100173844A1 (en) 2010-07-08
JP5175103B2 (en) 2013-04-03
JP2008519809A (en) 2008-06-12
KR20070084194A (en) 2007-08-24
AU2005303777B2 (en) 2010-12-16
CN105832658B (en) 2020-07-31
CA2586771A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
BRPI0517341A (en) shelf stable pharmaceutical composition, methods for the preparation of a pharmaceutical composition, for the treatment of hyperglycemia, for the treatment of obesity, beta cell deficiency, igt or dyslipidemia, for the preparation of a stable solution of a glp-1 compound, for the preparation of a stable glp-1 compound and for the preparation of a shelf stable pharmaceutical composition of a glp-1 compound, stable solution of a glp-1 compound, and use of a stable solution of a glp-1 compound
CL2008002227A1 (en) Substituted 4 - [(8r) -4-amino-5-oxo-7,8-dihydrorimido [5,4-f] [1,4] oxazepin-6 (5h) -yl] phenyl derivative compounds; its pharmaceutical composition; and use of the compounds in the treatment of type 2 diabetes, particularly useful for treating obesity.
NO20064584L (en) Tetrahydropyridoindolderivater
NO20073059L (en) 2,3,4,9-TETRAHYDRO-1H-CARBAZOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
BRPI0511420A (en) sulfonylethyl phosphorodiamidates
DK1636236T3 (en) Pyrazolo-quinazoline derivatives, a process for their preparation, and their use as kinase inhibitors
BR112012006252A2 (en) "crystalline forms of abt-263 and solvates for use in the treatment of bcl-2 protein related diseases".
ECSP099662A (en) New Derivatives of 3 - ([1,2,4] triazolo [4,3-a] pyridin-7-yl) benzamide
DK1791532T3 (en) Composition in micropellet form with controlled release of physiologically active substances, process for their preparation and use in the zootechnical sector
CL2012003075A1 (en) Pharmaceutical composition in pazopanib solution, stable and for ophthalmic use; method for the preparation of said solution.
CL2008002051A1 (en) Compounds derived from isoxazole-4-methoxy, triazole-4-methoxy or pyrazole-4-methoxy, with agonist activity of the x-farnesoid receptor (fxr); pharmaceutical composition containing them; and the use of the compounds in the preparation of drugs useful for the treatment of dyslipidemia and related diseases.
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
ECSP088350A (en) PIRAZOLOPIRIMIDINAS AS INHIBITORS OF PROTEIN KINASES
CL2008001103A1 (en) Compounds derived from [1,2,3] triazolo [4,5-b] pyridine-corboxamides and [1,2,3] triazolo [4,5-d] pyrimidine-carboxamides, megl and faah inhibitors; preparation procedure; pharmaceutical composition; and its use in the treatment of acute or chronic pain, vertigo, vomiting, nausea, metabolic syndrome, dyslipidemia, among others.
CL2009001936A1 (en) Pyridazine derived compounds, 11beta-hsd1 inhibitors; pharmaceutical composition; preparation procedure; and use in the treatment of diabetes, obesity, dyslipidemia, eating disorders and hypertension (divisional application 1720-2006).
WO2011104381A3 (en) Stable antibody containing compositions
TW200806289A (en) Sustained-release formulation of zonisamide
BRPI0510428A (en) methadone topical compositions and processes for using them
CL2007003756A1 (en) COMPOUNDS DERIVED FROM PIRAZOLO-QUINAZOLINA SUBSTITUTED, MODULATORS OF THE ACTIVITY OF PROTEIN KINASES; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT OF CANCER.
CL2007003523A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
CR8778A (en) SUGAR COATINGS AND METHODS FOR THESE
BRPI0908887A2 (en) liquid pharmaceutical composition, pharmaceutical container, methods for preparing and manufacturing a pharmaceutical composition, and use of a pharmaceutical composition
DE602005021770D1 (en) INDOLE-1-YL-ACETIC DERIVATIVES
BRPI0816097A2 (en) pharmaceutical composition, method for treating erythema in a patient with rosacea, and, use of a composition.
IL175568A (en) Tyrosine kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15W Others matters related to applications: legal action concerning application

Free format text: "INPI NO 52402.010213/2021-53 ORIGEM: 22A VARA FEDERAL CIVEL DA SJDF (TRF1) PROCESSO NO: 1070255-48.2021.4.01.3400 NULIDADE DE ATO ADMINISTRATIVO AUTOR: NOVO NORDISK A/S E NOVO NORDISK FARMACEUTICA DO BRASIL LTDA. REU(S): INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL "